Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

25.81 -0.62

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.13

Massimo

26.19

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+25.43% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

593M

2.6B

Apertura precedente

26.43

Chiusura precedente

25.81

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 23:52 UTC

News

Boeing Co secures over $711 million in U.S. defense contract modifications, boosting investor sentiment. Shares are higher in after-market trading.

14 ago 2026, 23:51 UTC

News

PayPal is in advanced talks for a potential sale to Stripe and Advent, following a proposal of $60.50 per share. Shares are higher in after-market trading.

14 ago 2026, 23:51 UTC

News

Tyson Foods will close its beef facility in Joslin, Illinois, resulting in about 2,500 job losses, as shares trade lower in after-market hours.

14 ago 2026, 23:46 UTC

News

Replimune Group Inc shares are lower in after-market hours amid negative sentiment from a securities fraud lawsuit related to its RP1 application.

14 ago 2026, 23:46 UTC

News

Delek US Holdings shares rose in after-market hours following Delek Logistics Partners' $230 million public offering of common units at $50.00 each.

14 ago 2026, 23:46 UTC

News

Patterson-UTI Energy reported 98 drilling rigs operating in July. Shares rose in after-market trading, reflecting strong activity and nearing the upper end of their one-month range.

14 ago 2026, 23:46 UTC

News

Kraft Heinz Co shares are lower in after-market trading following a $100 million marketing announcement and concerns over July's U.S. retail sales drop.

14 ago 2026, 23:41 UTC

News

Elliott Investment Management increased its stake in Hewlett Packard Enterprise by 17.7%, contributing to higher after-market trading for the shares.

14 ago 2026, 23:36 UTC

News

Dynatrace shares are higher in after-hours trading following Starboard Value's SEC filing disclosing an 8.9 million share stake.

14 ago 2026, 23:31 UTC

News

Texas Pacific Land Corp shares are higher in after-market hours, with a current price of $358.89 and a market capitalization of $24.75 billion.

14 ago 2026, 23:31 UTC

News

Jana Partners disclosed a new stake in Rapid7 Inc, acquiring over 6.7 million shares. Shares advanced during after-market hours following the announcement.

14 ago 2026, 23:21 UTC

News

MongoDB Inc. showcases AI focus with new Atlas Managed MCP Server tools and Voyage AI features. Shares are little changed in after-market trading.

14 ago 2026, 23:21 UTC

News

Constellation Brands shares are trading lower after Berkshire Hathaway dissolved its stake, contributing to negative sentiment amid broader weakness in the Distillers & Vintners sector.

14 ago 2026, 23:21 UTC

News

Embecta Corp shares are lower in after-market hours amid negative sentiment from two class action lawsuits alleging securities fraud and disappointing second-quarter guidance.

14 ago 2026, 23:11 UTC

News

Lattice Semiconductor granted over 414,000 RSUs and PRSUs to new employees as part of its equity incentive plan. Shares are trading roughly flat in after-market hours.

14 ago 2026, 23:11 UTC

News

Lone Pine Capital LLC reduced its stake in McKesson Corp by 85.3% to 57,851 shares, contributing to the stock's decline in after-market trading.

14 ago 2026, 23:06 UTC

News

Berkshire Hathaway raised its stake in Delta Air Lines by 44%, now holding 57.3 million shares. Shares are trading higher in after-market hours.

14 ago 2026, 23:06 UTC

News

Mastercard proposes a plan for Brazilian payment processors to absorb R$2.5 billion in losses from Banco Master’s collapse, as shares decline in after-market trading.

14 ago 2026, 23:06 UTC

News

Viking Global Investors has cut its stake in Walt Disney by a significant amount, while ValueAct Holdings has fully exited its position. Shares are lower in after-market trading.

14 ago 2026, 23:02 UTC

News

Target shares lower in after-market trading despite Telsey Advisory Group's Outperform rating and raised price target to $170. Broader market weakness weighs on performance.

14 ago 2026, 23:01 UTC

News

ServiceNow Inc shares fell in after-market trading to about $124.03 amid broader market concerns following a drop in U.S. retail sales.

14 ago 2026, 23:01 UTC

News

Berkshire Hathaway's Form 13F filing revealed a new position in DR Horton, boosting investor interest and driving shares higher in after-hours trading.

14 ago 2026, 23:01 UTC

News

Warner Bros Discovery Inc. shares declined in after-market hours amid regulatory scrutiny over its merger with Paramount Skydance Corp, facing opposition from state attorneys general.

14 ago 2026, 23:01 UTC

News
Social Media

Genco Shipping & Trading shares lower in after-market trading following Diana Shipping's withdrawal of its acquisition offer, citing unrealistic demands from Genco's Board.

14 ago 2026, 23:01 UTC

News
Social Media

Berkshire Hathaway increased its stake in Macy's to 7.3 million shares, contributing to positive sentiment as shares advanced in after-market trading.

14 ago 2026, 23:01 UTC

News

Baker Hughes Co shares are lower in after-market hours amid rising oil and gas rig counts and concerns over a decline in U.S. retail sales.

14 ago 2026, 23:01 UTC

News

MSCI Inc. shares are higher in after-market trading, reflecting a cumulative gain since Friday's close and a market capitalization of $41.38 billion.

14 ago 2026, 23:01 UTC

News

Berkshire Hathaway increased its stake in New York Times Co. by 3.7%, contributing to a modest rise in after-market trading.

14 ago 2026, 23:01 UTC

News

NIO shares rose during after-market hours to about $4.50, as options sentiment showed mixed signals ahead of the upcoming earnings report.

14 ago 2026, 23:01 UTC

News

Realty Income Corp closed a $1.0 billion private offering of convertible senior notes, with proceeds for share repurchases and debt repayment. Shares are higher in after-market trading.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

25.43% in crescita

Previsioni per 12 mesi

Media 32.65 USD  25.43%

Alto 45 USD

Basso 21.6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat